Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Davunetide intranasal

Drug Profile

Davunetide intranasal

Alternative Names: AL-108; NAP; NAPVSIPQ

Latest Information Update: 16 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institutes of Health (USA); Tel Aviv University
  • Developer Allon Therapeutics
  • Class Antidementias; Eye disorder therapies; Neuropeptides; Neuroprotectants; Nootropics
  • Mechanism of Action Microtubule-associated protein modulators; Tau protein inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity No
  • Available For Licensing Yes - Alzheimer's disease; Mild cognitive impairment; Schizophrenia

Highest Development Phases

  • Discontinued Alzheimer's disease; Mild cognitive impairment; Parkinson's disease; Progressive supranuclear palsy; Schizophrenia

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 16 Jul 2013 Allon Therapeutics has been acquired by Paladin Labs
  • 18 Dec 2012 Efficacy data from a phase II/III clinical trial in Progressive supranuclear palsy released by Allon Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top